Universal Ibogaine Targets Fundraising for Clinical Trials
Company Announcements

Universal Ibogaine Targets Fundraising for Clinical Trials

Universal Ibogaine Inc (TSE:IBO) has released an update.

Universal Ibogaine Inc. is set to raise $350,000 through a private placement offering of common shares, aimed at financing its ibogaine-based clinical trial application with Health Canada and for general working capital. Following the approval at the annual meeting of shareholders, the company re-elected its board members, appointed MNP LLP as auditors, and approved its 2024 Employee Equity Incentives Plan and Stock Option Plan.

For further insights into TSE:IBO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskUniversal Ibogaine Announces Share Issuance
TipRanks Canadian Auto-Generated NewsdeskUniversal Ibogaine Completes Funding Round
TipRanks Canadian Auto-Generated NewsdeskUniversal Ibogaine Targets Opioid Treatment Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!